CELL HANDLER™ 2 to Debut by Yamaha Motor
Yamaha Motor Co., Ltd. (Tokyo: 7272) announced that it will exhibit the CELL HANDLER™ 2, a cell picking and imaging system, at marking the product's first overseas exhibition.
Latest Press Releases
The 'Press Releases' section offers the latest product-specific and company-related updates to our esteemed clients, providing them with a valuable resource. Members can leverage this platform for quick, efficient, and effective visibility.
— Our press release programs complement our content distribution initiatives, ensuring strong positioning across major media outlets and social media channels. This enhances the visibility of your message within the global pharmaceutical industry.
— Our press release programs complement our content distribution initiatives, ensuring strong positioning across major media outlets and social media channels. This enhances the visibility of your message within the global pharmaceutical industry.
SN BioScience receives FDA IND clearance to propel SNB-101 into Phase 2
SN BioScience announced that its lead asset SNB-101 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a Phase 1b/2 clinical trial. This achievement follows the designation of SNB-101 as an orphan drug for small cell lung cancer in 2023 and its Fast Track designation in 2024.
CorriXR Therapeutics names Jan Case as Chief Operating Officer
CorriXR Therapeutics, Inc., a pioneering biotherapeutics company focused on oncology and innovative technologies to overcome drug resistance in solid tumors, announced that Jan Case has joined the Company as Chief Operating Officer.
Genesis Medtech's World's First 90° Articulation Powered Stapler Revolutionizes Surgical Precision and Achieves Chinese Approval
Genesis Medtech is proud to announce that iReach Omnia, the world's first powered stapler with 90° articulation capability, has been approved for market release in China by the National Medical Products Administration (NMPA).
Orthogon Therapeutics secures $5.2M funding to develop the first oral treatment for BK polyomavirus
Orthogon Therapeutics, a developer of novel antiviral medicines, announced the closing of an oversubscribed financing round, exceeding its $5M target and bringing total funding to over $25M. This funding will accelerate the development of its first-in-class treatments for managing BK virus reactivation in transplant patients.
Revolutionizing plasmid DNA purification with automated systems for optimal yields and low endotoxin levels
GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell therapies announced that its Life Sciences subsidiary, GenScript, has introduced a next generation DNA purification platform:
Two-year data confirms Vista Cardiac provides faster, more reliable MRI scans, enhancing diagnostic efficiency
Vista, a leader in intelligent MRI acquisition software, announced two-year clinical results showing Vista Cardiac significantly improves workflow efficiency, ensures high-quality and consistent imaging, and scales cardiac MRI (CMR) programs to expand access to more patients.
Bruker Introduces Dimension Nexus™ Atomic Force Microscope
Bruker Corporation announced the launch of the Dimension Nexus™ atomic force microscope (AFM). Dimension Nexus is the newest addition to the industry-leading Dimension® AFM product line, which has had more than 4600 systems installed around the world.
Medtronic receives FDA clearance for new InPen™ app, paving the way for its Smart MDI system launch with Simplera™ CGM
Medtronic plc a global leader in healthcare technology, announced U.S. Food and Drug Administration (FDA) clearance for its new InPen™ app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system with the Simplera™ continuous glucose monitor (CGM).
Jazz Pharmaceuticals secures U.S. FDA approval for Ziihera® (zanidatamab-hrii), a treatment for adults with HER2-positive metastatic biliary tract cancer
Jazz Pharmaceuticals plc announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.